BOSTON, MAY 13, 2019 – Life Biosciences announced today that Amit Shashank is joining the company as General Counsel. Mr. Shashank is a strategically-oriented global leader, with more than twenty years of international experience in technology and business services organizations – both private and public – and demonstrated expertise that spans complex mergers and acquisitions, commercial transactions, and all phases of corporation financings including initial public offerings (IPOs). Amit has broad legal and compliance experience across a number of industries including healthcare, financial services, telecommunications and semiconductors.
“I am thrilled to be joining Life Biosciences at this moment in the company’s development,” said Mr. Shashank. “Life Biosciences has both a sweeping mission – to bring extended health spans to everyone in the world – and a brilliant research team to accomplish it. The company’s pending research and its focus on the underlying pathways of aging offer a paradigm shift from the existing model of drug discovery and development.”
“We couldn’t be more excited to welcome Amit to the team,” said Mehmood Khan, the Chief Executive Officer of Life Biosciences. “At a company like ours conducting breakthrough research that will require complex regulatory approvals and is actively pursuing strategic alliances and other business opportunities, the role of General Counsel is of critical importance. I can’t think of anyone more perfectly suited to this role than Amit.”
Most recently, Mr. Shashank served as Executive Vice President, General Counsel and Secretary of Aricent, a global R&D engineering and design powerhouse with over 10,000 employees. In 2018, Mr. Shashank was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies (EPA: ALT) for $2.0 billion. Prior to Aricent, Amit served as Executive Vice President, General Counsel, Chief Compliance Officer and Secretary at ExlService Holdings, Inc. (NASDAQ: EXLS), an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company.
Mr. Shashank began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law. Amit is also a Rhodes Scholar.
- Life Biosciences Overview –
Life Biosciences is dedicated to tackling eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase health spans and reduce disease for everyone, including companion animals.
Life Biosciences has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. Its Daughter companies have access to Life Biosciences’ centralized resources, including experienced management and drug development expertise, access to LifeLabs, a state-of-the-art research facility in Cambridge, Massachusetts, and the full resources of Lua, a HIPAA-compliant communications platform which also provides data analytics to support and connect Life Biosciences’ laboratory and teams across the United States, Europe, Asia, and Australia.
For more information on Life Biosciences, please visit www.lifebiosciences.com.